5-Amino-1MQ: The NNMT Inhibitor the Longevity Crowd Won't Shut Up About

5-Amino-1MQ is the weird one. It isn't a peptide — it's a small-molecule NNMT inhibitor — but it sits on peptide catalogs because it lives in the same neighborhood of thought: fat loss, NAD+ preservation, adipose-tissue biology, the slow quiet machinery of aging. The longevity forums won't stop talking about it. The body-comp forums took it up because of the rodent fat-loss data. Most people who try it are running it for both.

This is what the community has actually figured out.

What it is, in one paragraph

5-Amino-1MQ inhibits NNMT (nicotinamide N-methyltransferase), an enzyme overexpressed in white adipose tissue and some cancers. NNMT chews up SAM (the methyl-donor currency) and nicotinamide (a NAD+ building block) to make 1-methylnicotinamide. Blocking it keeps more methyl groups and more nicotinamide in rotation — which in rodent studies cashed out as less body fat, better insulin sensitivity, and healthier aging markers without appetite suppression. It's oral, it's small, and it's charged — a quaternary ammonium compound, not a peptide.

Dosing: what people actually do

Oral, once daily, usually in the morning on an empty stomach. Dose ranges on the forums:

• Starting: 50 mg/day for the first 1–2 weeks
• Standard: 100–150 mg/day
• Aggressive: 200–250 mg/day (some split AM/PM)
• Maintenance/longevity-only: 50–100 mg, 3–5 days/week

Cycles run 8–12 weeks, with some people cruising long-term at lower doses. Loss pace in user logs is typically 0.5–1.5 lb/week of fat, on top of whatever diet and training are doing — it's an accelerator, not a stand-alone weight-loss drug.

"The honest answer is that I only noticed it clearly when I was already dialed in on training and food. At that point, 150 mg/day peeled off about two pounds a month that I didn't expect. Not magic. Useful." — forum user

What it pairs with

• GLP-1s (Semaglutide, Tirzepatide, Retatrutide) — this is the combo the forums obsess over. GLP-1 handles appetite and caloric deficit; 5-Amino-1MQ handles adipocyte-level fat metabolism. Early anecdotes suggest they're additive
• NAD+ precursors (NR, NMN) — the theoretical pairing, since NNMT inhibition preserves nicotinamide upstream of NAD+ synthesis. Data is thin but the logic is sound
• MOTS-c, FGF21 analogs — metabolic stack for the longevity-focused crowd
• Tesofensine, AOD-9604 — people running comprehensive fat-loss protocols

Red flags and side effects

Clinical human safety data is limited. What the forums report:

• GI discomfort — mild, usually dose-dependent
• Energy shifts — some report mild stimulation, others nothing
• Skin/complexion changes — occasionally reported, mechanism unclear
• Nothing dramatic — this is one of the better-tolerated compounds in the space, based on anecdote

Longer-term concern the thoughtful users flag: NNMT isn't only expressed in adipose. Inhibiting it systemically has unknown effects on other tissues over years of use. Nobody knows yet.

The honest limits

• The data is mostly rodent. Human RCTs don't exist. Everything about "translation to humans" is assumption
• It's a small molecule, not a peptide — bioavailability, absorption, and stability behave differently. Oral works, but product quality and encapsulation matter
• Fat loss without appetite suppression is real in animals but looks subtler in humans. Expect "useful adjunct," not "miracle"
• Because it's cross-catalogued with peptides, sourcing quality ranges from pharmaceutical-grade to "mystery powder." COA or don't bother

Where to go next

• For the mechanism, NNMT biology, and the animal study references, see the Pepperpedia 5-Amino-1MQ entry.
• For real-world logs — especially stacks with GLP-1s — the Optimization forum has the active threads.
• Dose-by-weight and capsule splits? PepperCalc handles the conversions.